Patients and Methods
The study population consisted of 5,629 consecutive men who underwent RP and staging lymphadenectomy at the Johns Hopkins Hospital between January 1, 2006 and July 30, 2011 and met inclusion criteria. • Polychotomous logistic regression analysis was used to predict the probability of each pathologic stage category: organ-confined disease (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+) based on preoperative criteria. • Preoperative variables included biopsy Gleason score (6, 3+4, 4+3, 8, and 9-10), serum PSA (0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0, greater than 10.0 ng/mL), and clinical stage (T1c, T2c, and T2b/T2c). • Bootstrap re-sampling with 1000 replications was performed to estimate 95% confidence intervals for predicted probabilities of each pathologic state.
Results
• The median PSA was 4.9 ng/mL, 63% had Gleason 6 disease, and 78% of men had T1c disease.
• 73% of patients had OC disease, 23% had EPE, 3% had SV+ but not LN+, and 1% had LN+ disease. Compared to the previous Partin nomogram, there was no change in the distribution of pathologic state. • The risk of LN+ disease was significantly higher for tumours with biopsy Gleason 9-10 than Gleason 8 (O.R. 3.2, 95% CI 1.3-7.6). • The c-indexes for EPE vs. OC, SV+ vs. OC, and LN+ vs.
OC were 0.702, 0.853, and 0.917, respectively. • Men with biopsy Gleason 4+3 and Gleason 8 had similar predicted probabilities for all pathologic stages. • Most men presenting with Gleason 6 disease or Gleason 3+4 disease have <2% risk of harboring LN+ disease and may have lymphadenectomy omitted at RP.
Introduction
The 'Partin tables' use commonly available preoperative data -serum PSA level, clinical stage and biopsy Gleason score -to predict pathological stage at radical prostatectomy (RP). The original Partin tables used preoperative data from men who were treated between 1982 and 1991; so most were diagnosed in the pre-PSA era [1] . Updates to the Partin tables reflected the changing nature of prostate cancer diagnosis in the USA [2-6] and abroad [7] [8] [9] [10] [11] [12] .
With the advent of PSA screening, the incidence of prostate cancer in the USA rose dramatically over the subsequent two decades, resulting in considerable changes in the clinical and pathological stage of men diagnosed with prostate cancer [13] . Contemporary men present with lower PSA, lower clinical stage and higher likelihood of harbouring organ-confined tumours than men diagnosed with prostate cancer in the pre-PSA era [4, 14, 15] .
Over the past 5 years, men presenting with prostate cancer are more likely to have a PSA level <4.0 ng/mL and less likely to present with PSA > 10.0 ng/mL. In addition, an update to the , men in the current cohort were more likely to have PSA Յ 4 ng/mL (30% vs 25%), more likely to have Gleason score >6 on both biopsy (37% vs. 23%) and prostatectomy (50% vs. 36%), and were virtually identical with respect to the distributions of clinical stage and pathologic stage.
Results
As in our previous tables, we combined clinical stage T2b and T2c, given the small fraction of T2c patients (1%) and the similar association with pathological stage (data not shown). Because of the possibility that the 2005 revision to the Gleason scoring system altered the prognostic information for specific categories, we compared models with Gleason 8-10 combined with a model that assigned separate categories to Gleason 8 and Gleason 9-10. The latter model showed higher risk for Gleason 9-10. For example, the odds ratios and 95% CIs for Gleason 9-10 vs 8 were 3.2 (1.3-7.6) for risk of LN+ vs OC, 1.8 (0.9-3.9) for SV+ vs OC, and 1.2 (0.7-2.1) for EPE vs OC. Hence, we developed the tables based on the model that separated Gleason 8 from 9-10. Table 2 presents the predicted probabilities from the polychotomous logistic regression model and the bootstrapped 95% CIs. Each cell shows the predicted probabilities for each of the pathological stage categories for specific clinical stage, PSA level and Gleason score. For example, for men with T1c tumours, the probability of OC tumour ranges from 23% (for men with biopsy Gleason score 9-10 and PSA > 10 ng/mL) to 93% (for men with Gleason score 6 and PSA Յ 2.5 ng/mL). In contrast, the predicted risk of LN+ is no more than 3% for T1c tumours with biopsy Gleason score <9 regardless of PSA. The c-indexes for EPE vs OC, SV+ vs OC and LN+ vs OC were 0.702, 0.853 and 0.917, respectively. Although discrimination is quite good for SV+ and LN+ it is not surprising that EPE exhibits lower discrimination, because a significant fraction of EPE cases exhibited only focal areas of extension and probably have a prognosis similar to OC [20].
We also combined PSA categories 6.1 to 8.0 and 8.1 to 10.0 ng/mL in a single predictor category because clinical 1 (0-1) 4 (2-5) 6 (4-9) 6 (4-10) 10 (5-16) 1 (1-2) 6 (4-8) 9 (6-13) 9 (5-14) 14 (8-21) Several interesting trends are apparent in these tables. Within the range of PSA levels from 2.6 to 10.0 ng/mL, the predicted probability of SV+ or LN+ is relatively insensitive to PSA, but probabilities increase twofold to threefold when comparing PSA Յ 10 with >10.0 ng/mL. In our previous version of these tables a similar trend was observed for LN+ but not for SV+, which tended to increase more linearly. In a similar vein, the biggest increases in probability of EPE occur for biopsy Gleason score 6 vs 3+4, with much smaller increases above 3+4. Again, in our previous version the risk of EPE tended to increase more linearly with biopsy Gleason. Finally, regardless of clinical stage or PSA level, men with biopsy Gleason score 4+3 and 8 had similar predicted probabilities for all pathological stages. Figure 1 shows the calibration plots comparing predicted and actual probabilities for each pathological stage. The model tended to overestimate the probability of OC and underestimate the probability of EPE, though it was very accurate for predicted probability of OC > 80% and EPE < 20%. Predicted probabilities of SV+ and LN+ were close to the observed values for probability Յ20%. Only 2.2% of participants had predicted probability of SV+ > 20% and only 0.6% had predicted probability of LN+ > 20%, so model predictions for advanced stage are likely to be accurate.
Discussion
The use of nomograms to predict clinical outcomes assumes that contemporary patients will behave similarly to patients with comparable clinical characteristics in the nomogram population [21] . As PSA screening became widespread, a continuously increasing proportion of men diagnosed with prostate cancer have presented with localized disease [22] amenable to surgical therapy [23], making older nomograms progressively obsolete.
In the current report, the distribution of men in each pathological stage is identical to that in our previous 2007 iteration of these tables [4] . Hence, stage migration appears to have stabilized at our institution. The predicted probabilities from the current nomogram are similar to those of our 2007 report, which used a patient cohort treated from 2000 to 2005 [4] . The most important differences are that risk of advanced stage is higher for Gleason 9-10 than Gleason 8 tumours, Gleason 4+3 and 8 tumours exhibit similar risks for each category of clinical stage and PSA, and the prognostic impact of PSA level >10 ng/mL for predicting pT3 and N1 disease is particularly strong.
In the contemporary population, fewer men presented with biopsy Gleason 6 disease (63% vs 77%, respectively) as well as pathological Gleason sum 6 disease (50% vs 65%, respectively) than in the previous Partin table population, and more men presented with 'high-risk' disease of 4+3 or higher on the biopsy (15% vs 9%, respectively) and the prostatectomy (20% vs 13%, respectively) than in the previous Partin table population. Despite the shift to higher grade, the prevalence of high-risk PSA values (>10 ng/mL) was somewhat lower (8% vs 12%, respectively) than in the previous Partin tables. This, and the lack of change in advanced stage cases, supports the notion that the grade changes are a result of the update to the Gleason scoring system, rather than an increase in more biologically aggressive disease. However, increasing employment of active surveillance among men with low-risk disease [24, 25] and increased use of RP among those with high-risk disease [26-29] probably play a role as well [24, 30] . Previous studies have found the new Gleason scoring system to provide more accurate predictions of biochemical recurrence as well as greater correlation between biopsy and pathological Gleason score [17, 18, 31, 32] . The current nomogram may also have increased accuracy resulting from the new Gleason scoring system, though this remains to be verified in an independent patient population.
In recent years the most common use of the Partin nomograms has been in deciding to perform a lymphadenectomy at the time of RP. In a recent head-to-head comparison of the 2007 Partin tables with the National Comprehensive Cancer Network lymph node invasion nomogram [33] and the D'Amico risk classification [34] for the purpose of predicting LN+ disease in a lymphadenectomy, the Partin tables showed the greatest net benefit for a decision threshold probability of LN+ Յ 4%. That is, when the decision to perform lymphadenectomy is based on predicted probability of LN+ that exceeds a threshold set at Յ4%, predictions from the Partin tables gave the best ratio of appropriate to inappropriate lymphadenectomies [35, 36] . It should be noted that most men in the study population underwent limited pelvic lymph node dissection rather than extended pelvic lymph node dissection.
Though lymphadenectomy is generally well tolerated, an increased risk of lymphocoele [37] , thromboembolism [38] and, rarely, injury to the ureter, pelvic nerves or vessels [39] has been reported. Overall complication rates range from 2 to 20% for limited lymphadenectomy, with higher complication rates reported in extended lymphadenectomy [40] [41] [42] . To limit complications in patients unlikely to benefit from lymphadenectomy, the National Comprehensive Cancer Network suggests that lymphadenectomy may be excluded if the risk of lymph node involvement is <2% [43] , a policy which has been adopted for patients at one high-volume centre [44] . Abdollah et al. [35] showed that the 2007 Partin tables are particularly accurate within this range, and given the close calibration of the current model for predicted probabilities of N+ < 20% (see Fig. 1 ) it is likely that the current model will continue to be an excellent tool for the decision to perform lymphadenectomy. Using the current tables and a cut-off of <2%, lymphadenectomy may be omitted in all men with Gleason 6 disease unless they have both PSA level >10 ng/mL and clinical stage T2b or greater. Men with Gleason 3+4 disease and clinical stage T1c may avoid lymphadenectomy unless PSA levels are >10 ng/mL. When patients have Gleason 3+4 and palpable disease, lymphadenectomy should be performed in most cases, and in our opinion, all men with Gleason 4+3 or greater disease should undergo lymphadenectomy regardless of clinical stage or serum PSA.
Since the publication of our previous version of the Partin tables there is an increasing trend toward the use of active surveillance to delay or forgo definitive treatment. With the recent US Preventive Services Task Force report on prostate cancer screening and over-treatment [45] , and the National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer [25], there is increased deliberation about the benefits vs harms of treatment for low-risk disease. A major use of the tables in the past was to predict the likelihood of low-risk disease that was curable by surgery. If additional evidence accrues that many men with low-risk disease are treated without benefit, then the use of the tables may shift toward identifying men with intermediate-to high-risk disease for whom the ratio of treatment benefit to harm may be greatest, or to identify men with low-to intermediate-risk disease who may benefit from active surveillance.
A limitation of the current analysis is that the data represent the demographics of the RP population at a single tertiary centre rather than that of the general population of men with prostate cancer. Whether the pathological stage distribution seen at our centre reflects a new equilibrium for RP candidates remains unclear, as other institutions have actually found decreasing OC disease over time [24] . Furthermore, whether these data reflect that pathological stage has stabilized only in those patients undergoing RP or all prostate cancer patients is unclear.
In conclusion, the current analysis represents an update of the 'Partin tables' based on the population of men treated from 2006 to 2011 at our institution. Pathological stage did not change between RP specimens from 2006 to 2010 and those from 2000 to 2005, possibly indicating a new equilibrium of pathological stage. Urologists may use these nomograms to predict pathological stage as a treatment decision aid for men newly diagnosed with prostate cancer. 
